GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a Phase III study for its PD-1-blocking antibody Jemperli (dostarlimab) in the treatment of primary advanced or recurrent endometrial cancer. The placebo-controlled trial aims to expand the current indication for frontline mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.
The first part of the study, which evaluates Jemperli in combination with chemotherapy followed by Jemperli maintenance, has already achieved the primary endpoint of overall survival (OS). The data indicates that the treatment reduced the risk of death by 31%, extending the median OS by 16.4 months.
The second part of the study included the PARP inhibitor Zejula (niraparib) in the maintenance therapy and successfully met its primary endpoint by reducing the risk of disease progression or death by 40%, leading to an improvement in progression-free survival (PFS) by 6.2 months.
GSK anticipates that the indication extension filing will be submitted for review in the US during the first half of 2024, potentially broadening the treatment options for patients with endometrial cancer.- Flcube.com
